LBA40_PR ARIEL3: a phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC).

2.50
Hdl Handle:
http://hdl.handle.net/10541/620700
Title:
LBA40_PR ARIEL3: a phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC).
Authors:
Ledermann, J; Oza, A; Lorusso, D; Aghajanian, C; Oaknin, A; Dean, A; Colombo, N; Weberpals, J; Clamp, Andrew R; Scambia, G; Leary, A; Holloway, R; O'Malley, D; Cameron, T; Maloney, L; Goble, S; Lin, K; Sun, J; Giordano, H; Coleman, R
Affiliation:
Gynaecological Oncology, University College London Cancer Institute and UCL Hospitals, London
Citation:
LBA40_PR ARIEL3: a phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC). 2017, 28(suppl_5): Ann Oncol
Journal:
Annals of Oncology
Issue Date:
Sep-2017
URI:
http://hdl.handle.net/10541/620700
DOI:
10.1093/annonc/mdx440.034
Additional Links:
http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx440.034/4109946/LBA40PRARIEL3-A-phase-3-randomised-doubleblind
Type:
Meetings and Proceedings
Language:
en
ISSN:
0923-7534; 1569-8041
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorLedermann, Jen
dc.contributor.authorOza, Aen
dc.contributor.authorLorusso, Den
dc.contributor.authorAghajanian, Cen
dc.contributor.authorOaknin, Aen
dc.contributor.authorDean, Aen
dc.contributor.authorColombo, Nen
dc.contributor.authorWeberpals, Jen
dc.contributor.authorClamp, Andrew Ren
dc.contributor.authorScambia, Gen
dc.contributor.authorLeary, Aen
dc.contributor.authorHolloway, Ren
dc.contributor.authorO'Malley, Den
dc.contributor.authorCameron, Ten
dc.contributor.authorMaloney, Len
dc.contributor.authorGoble, Sen
dc.contributor.authorLin, Ken
dc.contributor.authorSun, Jen
dc.contributor.authorGiordano, Hen
dc.contributor.authorColeman, Ren
dc.date.accessioned2017-11-23T21:40:56Z-
dc.date.available2017-11-23T21:40:56Z-
dc.date.issued2017-09-
dc.identifier.citationLBA40_PR ARIEL3: a phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC). 2017, 28(suppl_5): Ann Oncolen
dc.identifier.issn0923-7534-
dc.identifier.issn1569-8041-
dc.identifier.doi10.1093/annonc/mdx440.034-
dc.identifier.urihttp://hdl.handle.net/10541/620700-
dc.language.isoenen
dc.relation.urlhttp://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx440.034/4109946/LBA40PRARIEL3-A-phase-3-randomised-doubleblinden
dc.rightsArchived with thanks to Annals of Oncologyen
dc.titleLBA40_PR ARIEL3: a phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC).en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentGynaecological Oncology, University College London Cancer Institute and UCL Hospitals, Londonen
dc.identifier.journalAnnals of Oncologyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.